We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Fundamental aspects
-
1. Inflammation and tissue homeostasis
- Prof. Herman Waldmann
-
2. Introduction to the immune system
- Prof. Herman Waldmann
-
3. Hematopoiesis: the making of an immune system
- Prof. Paul J. Fairchild
-
4. Inflammation: purposes, mechanisms and development
- Prof. Pietro Ghezzi
-
5. Phagocytosis
- Dr. Eileen Uribe-Querol
-
6. Regulated cell death mechanisms and their crosstalk with the immune system 1
- Dr. Luis Alberto Baena-Lopez
-
7. Regulated cell death mechanisms and their crosstalk with the immune system 2
- Dr. Luis Alberto Baena-Lopez
- Innate immunity
-
11. Cells of the innate immune system
- Prof. Kevin Maloy
-
12. Microbial recognition and the immune response
- Dr. Dana Philpott
-
13. Toll-like receptor signalling during infection and inflammation
- Prof. Luke O'Neill
- Intercellular mediators
-
14. Chemokines
- Dr. James E. Pease
-
15. Cytokines
- Prof. Iain McInnes
-
16. IL-1 family cytokines as the canonical DAMPs of the immune system
- Prof. Seamus Martin
-
17. Glycans at the frontiers of inflammation, autoimmunity and cancer
- Prof. Salomé S. Pinho
-
18. Glycoimmunology
- Prof. Paula Videira
- Adaptive immunity B cells
-
21. Antigen recognition in the immune system
- Prof. Herman Waldmann
-
22. B cell biology
- Prof. Richard Cornall
-
23. Antibody structure and function: antibody structure
- Dr. Mike Clark
-
24. Antibody structure and function: antibody function
- Dr. Mike Clark
-
25. Antibody genes and diversity
- Dr. Mike Clark
-
26. In vivo antibody discovery and hybridoma technology
- Prof. Dr. Katja Hanack
-
27. Antibody engineering: beginnings to bispecifics and beyond
- Dr. Ian Wilkinson
-
29. The immunobiology of Fc receptors
- Prof. Mark Cragg
-
30. Immunoreceptors
- Prof. Anton van der Merwe
-
31. Affinity, avidity and kinetics in immune recognition
- Prof. Anton van der Merwe
- Adaptive immunity T cells
-
32. The thymus and T cell development: a primer
- Prof. Georg Holländer
-
33. Lineage decisions in the thymus: T cell lineage commitment
- Prof. Bruno Silva-Santos
-
34. Lineage decisions in the thymus: αβ and γδ T cell lineages
- Prof. Bruno Silva-Santos
-
35. CD4 T cell subsets
- Dr. Brigitta Stockinger
-
36. Cytotoxic T lymphocytes
- Prof. Gillian M. Griffiths
-
37. Gamma delta T-cells
- Prof. Bruno Silva-Santos
-
38. Tfh and Tfr cells
- Prof. Luis Graca
-
39. Tissue resident memory T cells (TRM)
- Dr. Marc Veldhoen
-
40. Mathematical modeling in immunology
- Prof. Ruy M. Ribeiro
- The importance of the MHC in immunity
-
41. The MHC and MHC molecules 1
- Prof. Jim Kaufman
-
42. The MHC and MHC molecules 2
- Prof. Jim Kaufman
-
43. Natural killer cells
- Dr. Philippa Kennedy
-
44. Human NK cells
- Prof. Lorenzo Moretta
-
46. NK cells in viral immunity
- Prof. Lewis Lanier
- Lymphocyte activation
-
47. Signal transduction by leukocyte receptors
- Dr. Omer Dushek
-
48. Immunological memory 1
- Prof. David Gray
-
49. Immunological memory 2
- Prof. David Gray
-
50. Studying immune responses “one cell at a time”
- Dr. Mir-Farzin Mashreghi
- Major cellular partners in immunity
-
51. The mononuclear phagocyte system - tissue resident macrophages: distribution and functions
- Prof. Emeritus Siamon Gordon
-
52. The mononuclear phagocyte system: tissue resident macrophages - activation and regulation
- Prof. Emeritus Siamon Gordon
-
53. Dendritic cells: professional antigen presenting cells
- Prof. Paul J. Fairchild
-
54. Mucosal immunology
- Prof. Daniel Mucida
- Immunological tolerance and regulation
-
55. Self-tolerance
- Prof. Herman Waldmann
-
56. Tolerance and autoimmunity
- Prof. Emerita Anne Cooke
-
57. The balance between intestinal immune homeostasis and inflammation
- Prof. Dr. Janneke Samsom
- Translational immunology - immune deficiency
-
58. Primary immunodeficiency disorders
- Dr. Smita Y. Patel
-
59. Changes in innate and adaptive immunity during human ageing 1
- Dr. Roel De Maeyer
-
60. Changes in innate and adaptive immunity during human ageing 2
- Dr. Roel De Maeyer
-
61. The aging immune system
- Prof. Ana Caetano
- Translational immunology - protection against pathogenic microbes
-
62. Immune responses to viruses
- Prof. Paul Klenerman
-
63. HIV and the immune system
- Prof. Quentin Sattentau
-
64. COVID-19: the anti-viral immune response
- Prof. Danny Altmann
-
65. Bacterial immune evasion
- Prof. Christoph Tang
-
66. The immunology underlying tuberculosis
- Prof. Thomas R. Hawn
-
67. Innate immunity to fungi
- Prof. Gordon D. Brown
-
68. Parasite immunity: introduction and Plasmodium
- Dr. Catarina Gadelha
-
69. Parasite immunity: Leishmania and Schistosoma
- Dr. Catarina Gadelha
-
70. Vaccination
- Dr. Anita Milicic
-
71. The history of vaccines 1
- Prof. Emeritus Anthony R. Rees
-
72. The history of vaccines 2
- Prof. Emeritus Anthony R. Rees
-
73. The history of vaccines 3
- Prof. Emeritus Anthony R. Rees
-
74. The science of vaccine adjuvants
- Dr. Derek O'Hagan
- Translational immunology - hypersensitivity, autoimmune disease and their management
-
75. Hypersensitivity diseases: type 1 hypersensitivity
- Prof. Herman Waldmann
-
76. Innate lymphoid cells in allergy
- Prof. Emeritus Shigeo Koyasu
-
77. Hypersensitivity diseases: type II-IV hypersensitivity
- Prof. Sara Marshall
-
78. Immune memory underlying lifelong peanut allergy
- Dr. Kelly Bruton
-
79. Memory B cells in allergy: B cell activation and response
- Dr. Kelly Bruton
-
80. Memory B cells in allergy: ontogeny, phenotype and plasticity
- Dr. Kelly Bruton
-
81. B cells at the crossroads of autoimmune diseases
- Dr. Xiang Lin
-
82. Interleukin-17: from clone to clinic
- Prof. Leonie Taams
-
83. Autoimmunity and type 1 diabetes
- Prof. Emerita Anne Cooke
-
84. What is new in type 1 diabetes?
- Prof. Åke Lernmark
-
85. Antibodies to control or prevent type 1 diabetes
- Dr. Robert Hilbrands
-
86. Monoclonal antibodies in haemato-oncology
- Prof. Mark Cragg
-
87. Therapeutic antibodies
- Dr. Geoffrey Hale
-
88. Endothelial cells: regulators of autoimmune-neuroinflammation
- Dr. Laure Garnier
-
89. Neuroimmunometabolism
- Prof. Ana Domingos
-
90. The immunology of multiple sclerosis
- Dr. Joanne Jones
-
91. Immunology of the peripheral nervous system: the inflammatory neuropathies
- Dr. Simon Rinaldi
-
92. Ocular immunology: an overview of immune mechanisms operating in the eye
- Dr. Eleftherios Agorogiannis
-
93. Understanding myasthenia gravis and advances in its management
- Prof. Henry J. Kaminski
-
94. The immunology underlying rheumatic diseases
- Dr. Hussein Al-Mossawi
-
96. Complement and lupus
- Prof. Marina Botto
-
97. Immune mechanisms in liver diseases
- Prof. Paul Klenerman
- Translational immunology - transplantation immunology
-
98. Principles of transplantation: overview of the immune response
- Prof. Emerita Kathryn Wood
-
99. Factors influencing outcomes in clinical transplantation 1
- Prof. Emerita Kathryn Wood
-
100. Factors influencing outcomes in clinical transplantation 2
- Prof. Emerita Kathryn Wood
- Translational immunology - cancer immunology
-
101. Cancer immunology
- Prof. Tim Elliott
-
102. Cancer immunotherapy
- Prof. Tim Elliott
-
103. Myeloid-derived suppressor cells in cancer
- Prof. Dmitry Gabrilovich
-
104. IL-2 in the immunotherapy of autoimmunity and cancer
- Prof. Thomas Malek
-
105. Latest advances in the development of CAR & TCR T-cell treatments for solid tumours
- Dr. Else Marit Inderberg
Printable Handouts
Navigable Slide Index
- Introduction
- SARS-CoV-2 dataset
- Models of protective immunity – the basics (1)
- Models of protective immunity – the basics (2)
- To start: a textbook view of a typical, generic human immune response to viral infection (1)
- To start: a textbook view of a typical, generic human immune response to viral infection (2)
- To start: a textbook view of a typical, generic human immune response to viral infection (3)
- SARS-CoV-2 outcomes
- Important questions
- Many have tried to model the ‘Correlates of Protection’ - COP
- Neutralising antibodies as the key COP
- Neutralising antibody levels
- Keeping track of antibodies
- Differential SARS-CoV-2 response
- Antibody response (1)
- Antibody response (2)
- T cell response signature of patients who suffer severe or fatal infection
- Mapping CD4 and CD8 T cell responses (1)
- Mapping CD4 and CD8 T cell responses (2)
- Mapping CD4 and CD8 T cell responses (3)
- Mapping CD4 and CD8 T cell responses (4)
- T cell and nAb responses are variable & discordant
- Waning immunity (1)
- Waning immunity (2)
- Variants of concern, VOC (1)
- Variants of concern, VOC (2)
- Variants of concern, VOC (3)
- Vaccines, variants, reinfections & boosting
- Many difficult choices ahead
- The road ahead
- Future vaccination approaches
- Summary points
- Thank you for listening
Topics Covered
- COVID-19
- SARS-CoV-2
- Immunity
- T cells
- B cells
- Antibodies
- Adaptive immune response
- Innate immune response
- Variants of concern
- Correlates of protection
- CD4
- CD8
- Immunisation
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Altmann, D. (2022, July 25). COVID-19: the anti-viral immune response [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved February 5, 2025, from https://doi.org/10.69645/KYKT9969.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Danny Altmann has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Respiratory Diseases
Transcript
Please wait while the transcript is being prepared...
0:00
Hello and welcome to
this talk on COVID-19:
the Anti-viral Immune Response.
I'm Danny Altmann.
I'm a professor of immunology
at Imperial College, London.
0:13
To start at the beginning.
For this talk, I'll
start quite basic
and build up to where we've
come to on the specifics
of the immune response
in the time of COVID.
If I date the dawn of
modern T cell and B cell
cellular immunology to
around 50 years ago,
since then immunologists
have learned
an enormous amount about
the nature of protective
immunity to some of the key
viruses that infect humans.
I guess we've accumulated
very large datasets
from studies looking at some of
the major pathogens
that have concerned us,
things like HIV, EBV,
CMV, flu, Hepatitis,
Dengue and even Zika.
But the coronavirus
family that we've
all become so obsessed with
in the last few years,
even including the common
cold coronaviruses
as well as SARS and MERS,
hadn't really been amongst the
most extensively
studied or understood.
But if you look at a little
graphic I've put here
of numbers of papers of content
published through 2019 to 2021,
you'll see that the
immunology of SARS-CoV-2,
the virus that causes COVID-19,
has become one of the
most massively studied
topics ever in human immunology.
1:32
Let's start at the
very beginning
and move on from there.
Obviously, when one learns
about protective immunity,
one tends to stratify it into
innate immunity and
adaptive immunity.
What do I mean by that?
Innate immunity refers to
intrinsic defence mechanisms
for recognising
microbial attack,
that something has
got into the body
from the environment
that shouldn't be there
and could be dangerous.
This includes everything from
the mucosal secretions
in the nasal pharynx,
but also white blood cells
such as neutrophils
and macrophages,
and the basic cellular responses
such as type 1 interferons.
These responses
are very rapid but
can be insufficient on their
own to prevent infection.
The key point is
they have no memory.
What do I mean by the
analogy of the word memory?
I mean that the
response will comprise
precisely the same features
and kinetics on the first,
second, or third encounter.
It doesn't get any
different or any better.
Also, the response isn't
particularly specific
to one virus
compared to another.